prof. dr. Karim Vermaelen
- ORCID iD
-
0000-0002-6787-8577
Show
Sort by
-
Phase Ia study of MIDRIX4-LUNG, a tetravalent autologous dendritic cell immunotherapy, in patients with metastatic non-small cell lung cancer
-
- Journal Article
- A1
- open access
Immune checkpoint-induced colitis : a single-center retrospective cohort study
-
- Journal Article
- A1
- open access
Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy : a dual approach for triple-negative breast cancer treatment
-
- Journal Article
- A1
- open access
A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens
-
- Journal Article
- A1
- open access
Defining the optimal setting for transcriptomic analyses on blood samples for response prediction in immunotherapy-treated NSCLC patients
-
- Journal Article
- A1
- open access
Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
-
MIDRIXNEO-LUNG : safety and immunogenicity of a neoantigen-presenting autologous dendritic cell therapy in resected NSCLC patients
(2023) JOURNAL OF THORACIC ONCOLOGY. In Journal of Thoracic Oncology 18(11, Supplement). p.S526-S526 -
Deconvolution-based estimation of immune cell fractions in blood for immunotherapy response prediction in non-small cell lung cancer patients
-
- Journal Article
- A1
- open access
Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
-
- Conference Paper
- C3
- open access
Cell type deconvolution as a strategy to develop a blood-based test for immunotherapy response prediction in lung cancer patients